Article
Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Aug 2017
Hijioka Susumu, Hosoda Waki, Matsuo Keitaro, Ueno Makoto, Furukawa Masayuki, Yoshitomi Hideyuki, Kobayashi Noritoshi, Ikeda Masafumi, Ito Tetsuhide, Nakamori Shoji, Ishii Hiroshi, Kodama Yuzo, Morizane Chigusa, Okusaka Takuji, Yanagimoto Hiroaki, Notohara Kenji, Taguchi Hiroki, Kitano Masayuki, Yane Kei, Maguchi Hiroyuki, Tsuchiya Yoshiaki, Komoto Izumi, Tanaka Hiroki, Tsuji Akihito, Hashigo Syunpei, Kawaguchi Yoshiaki, Mine Tetsuya, Kanno Atsushi, Murohisa Go, Miyabe Katsuyuki, Takagi Tadayuki, Matayoshi Nobutaka, Yoshida Tsukasa, Hara Kazuo, Imamura Masayuki, Furuse Junji, Yatabe Yasushi, Mizuno Nobumasa
Abstract excerpt
Purpose: Patients with pancreatic neuroendocrine neoplasm grade-3 (PanNEN-G3) show variable responses to platinum-based chemotherapy. Recent studies indicated that PanNEN-G3 includes well-differentiated neuroendocrine tumor with G3 (NET-G3). Here, we examined the clinicopathologic and molecular features of PanNEN-G3 and assessed the responsiveness to chemotherapy and survival.Experimental Design: A total of 100...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.